BRPI0713334A2 - suspensÕes aquaosas de tmc278 - Google Patents

suspensÕes aquaosas de tmc278 Download PDF

Info

Publication number
BRPI0713334A2
BRPI0713334A2 BRPI0713334-0A BRPI0713334A BRPI0713334A2 BR PI0713334 A2 BRPI0713334 A2 BR PI0713334A2 BR PI0713334 A BRPI0713334 A BR PI0713334A BR PI0713334 A2 BRPI0713334 A2 BR PI0713334A2
Authority
BR
Brazil
Prior art keywords
tmc278
aqueous suspensions
pharmaceutical compositions
prophylaxis
nanoparticles
Prior art date
Application number
BRPI0713334-0A
Other languages
English (en)
Inventor
Elvire Colette Baert Lieven
Albert Maria Carlo Dries Will
Bruno Schueller Laurent
Karel François Marc
Josef Maria Van Remoortere Peter
Original Assignee
Tibotec Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38833797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0713334(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals Ltd filed Critical Tibotec Pharmaceuticals Ltd
Priority to BR122020011487-8A priority Critical patent/BR122020011487B1/pt
Publication of BRPI0713334A2 publication Critical patent/BRPI0713334A2/pt
Publication of BRPI0713334A8 publication Critical patent/BRPI0713334A8/pt
Publication of BRPI0713334B1 publication Critical patent/BRPI0713334B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SUSPENSÕES AQUOSAS DE TMC278. A presente invenção refere-se a composições farmacêuticas para administração via injeção intramuscular ou subcutânea, compreendendo micro ou nanopartículas do composto TMC278 de NNRTI, suspensas em um veículo aquoso farmaceuticamente aceitável, e a uso de tais composições farmacêuticas no tratamento e profilaxia de infecção por HIV.
BRPI0713334-0A 2006-06-23 2007-06-22 Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV BRPI0713334B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122020011487-8A BR122020011487B1 (pt) 2006-06-23 2007-06-22 Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06115938.0 2006-06-23
EP06115938 2006-06-23
PCT/EP2007/056230 WO2007147882A2 (en) 2006-06-23 2007-06-22 Aqueous suspensions of tmc278

Publications (3)

Publication Number Publication Date
BRPI0713334A2 true BRPI0713334A2 (pt) 2012-03-06
BRPI0713334A8 BRPI0713334A8 (pt) 2018-01-02
BRPI0713334B1 BRPI0713334B1 (pt) 2024-02-20

Family

ID=38833797

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122020011487-8A BR122020011487B1 (pt) 2006-06-23 2007-06-22 Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação
BRPI0713334-0A BRPI0713334B1 (pt) 2006-06-23 2007-06-22 Uso de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]-amino]-2-pirimidinil]-amino]-benzonitrila para tratar ou prevenir infecção por HIV

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122020011487-8A BR122020011487B1 (pt) 2006-06-23 2007-06-22 Composição farmacêutica compreendendo micro ou nanopartículas do composto tmc278 e seu processo de preparação

Country Status (33)

Country Link
US (4) US20090176813A1 (pt)
EP (2) EP2040671B1 (pt)
JP (1) JP5292288B2 (pt)
KR (1) KR101406879B1 (pt)
CN (1) CN101478950B (pt)
AP (1) AP2618A (pt)
AR (1) AR061620A1 (pt)
AU (1) AU2007262941B2 (pt)
BR (2) BR122020011487B1 (pt)
CA (1) CA2654115C (pt)
CL (1) CL2007001847A1 (pt)
CY (1) CY1120564T1 (pt)
DK (2) DK2040671T3 (pt)
EA (1) EA021700B1 (pt)
ES (2) ES2989051T3 (pt)
FI (1) FI3366278T3 (pt)
HR (2) HRP20241265T3 (pt)
HU (2) HUE038797T2 (pt)
IL (1) IL195491A (pt)
JO (1) JOP20200160B1 (pt)
LT (2) LT3366278T (pt)
MX (1) MX2009000158A (pt)
NZ (1) NZ573291A (pt)
PE (1) PE20080210A1 (pt)
PL (2) PL3366278T3 (pt)
PT (2) PT3366278T (pt)
RS (2) RS65990B1 (pt)
SG (1) SG173315A1 (pt)
SI (2) SI3366278T1 (pt)
TW (1) TWI413521B (pt)
UA (1) UA97641C2 (pt)
UY (1) UY30431A1 (pt)
WO (1) WO2007147882A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
PT1981506E (pt) 2006-01-20 2013-06-25 Janssen R & D Ireland Tratamento a longo prazo da infeção pelo vih com tmc278
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EP2306980A2 (en) * 2008-06-30 2011-04-13 Tibotec Pharmaceuticals Powders for reconstitution
RU2546529C2 (ru) * 2008-12-24 2015-04-10 Тиботек Фармасьютикалз Имплантируемые устройства для лечения вич
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
SG10201704467SA (en) 2012-12-14 2017-06-29 Glaxosmithkline Llc Pharmaceutical compositions
EP3197430A1 (en) 2014-09-26 2017-08-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
JP6704058B2 (ja) * 2016-05-31 2020-06-03 タイメド・バイオロジクス・インコーポレイテッドＴａｉＭｅｄ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． プロテアーゼ阻害剤の長時間作用性医薬組成物
US10369129B2 (en) * 2016-05-31 2019-08-06 Taimed Biologics, Inc. Long acting pharmaceutical composition of protease inhibitor
TWI678203B (zh) * 2016-05-31 2019-12-01 中裕新藥股份有限公司 蛋白酶抑制劑之長效醫藥組合物
US11065198B2 (en) 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
JOP20200004B1 (ar) 2017-07-14 2023-09-17 Janssen Pharmaceutica Nv تركيبات طويلة المفعول
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
US20240277614A1 (en) 2020-07-09 2024-08-22 Janssen Pharmaceutica Nv Long-acting formulations
KR20230038521A (ko) 2020-07-09 2023-03-20 얀센 파마슈티카 엔.브이. 장기 작용 제형
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
WO2022109555A1 (en) 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
CA3196877A1 (en) * 2020-11-17 2022-05-27 Janssen Sciences Ireland Unlimited Company Treatment or prevention of a disease or disorder
AR127700A1 (es) 2021-11-17 2024-02-21 Janssen Sciences Ireland Unlimited Co Prueba de disolución
TW202406551A (zh) 2022-04-22 2024-02-16 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(一)
CA3249515A1 (en) 2022-04-22 2023-10-26 Janssen Sciences Ireland Unlimited Company LIQUID COMPOSITIONS
WO2023222755A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
WO2023222754A1 (en) 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Rilpivirine for use in the treatment or prevention of hiv infection
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2025054693A1 (pt) * 2023-09-14 2025-03-20 Instituto Hercílio Randon Premix funcional de nanopartículas, processo para sua obtenção, processo para modificação de propriedades de materiais e material com propriedades modificadas

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102124A (en) * 1976-07-12 1978-07-25 Swager William E Locking clevis or the like
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5046881A (en) * 1991-02-01 1991-09-10 Swager William E Lockable pin and clevis
US5114260A (en) * 1991-05-13 1992-05-19 Hart Judy L Clevis and screw pin type shackle with pin lock
US5272824A (en) * 1993-05-10 1993-12-28 Caterpillar Inc. Tooth assembly with leaf spring retainer
US5423138A (en) * 1994-04-04 1995-06-13 Caterpillar, Inc. Tip to adapter interface
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JP2005511629A (ja) * 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
PT1981506E (pt) * 2006-01-20 2013-06-25 Janssen R & D Ireland Tratamento a longo prazo da infeção pelo vih com tmc278

Also Published As

Publication number Publication date
US20160089369A1 (en) 2016-03-31
BRPI0713334B1 (pt) 2024-02-20
PT2040671T (pt) 2018-03-14
PE20080210A1 (es) 2008-04-11
AU2007262941B2 (en) 2013-11-21
CA2654115A1 (en) 2007-12-27
EP2040671A2 (en) 2009-04-01
CL2007001847A1 (es) 2008-02-08
SI2040671T1 (en) 2018-05-31
JP5292288B2 (ja) 2013-09-18
DK2040671T3 (en) 2018-05-07
ES2662068T3 (es) 2018-04-05
PL2040671T3 (pl) 2018-08-31
AU2007262941A1 (en) 2007-12-27
DK3366278T3 (da) 2024-09-23
HRP20241265T3 (hr) 2024-12-06
EP3366278B1 (en) 2024-08-07
AP2618A (en) 2013-03-18
TWI413521B (zh) 2013-11-01
UA97641C2 (xx) 2012-03-12
PL3366278T3 (pl) 2024-10-28
IL195491A (en) 2014-11-30
CA2654115C (en) 2015-12-22
JOP20200160B1 (ar) 2024-12-22
AP2008004682A0 (en) 2008-12-31
FI3366278T3 (fi) 2024-09-25
EP3366278A1 (en) 2018-08-29
HUE038797T2 (hu) 2018-11-28
ES2989051T3 (es) 2024-11-25
WO2007147882A3 (en) 2008-06-19
BR122020011487B1 (pt) 2024-02-20
AR061620A1 (es) 2008-09-10
JP2009541271A (ja) 2009-11-26
HRP20180629T1 (hr) 2018-06-01
WO2007147882A2 (en) 2007-12-27
SG173315A1 (en) 2011-08-29
US11389447B2 (en) 2022-07-19
CN101478950A (zh) 2009-07-08
EA021700B1 (ru) 2015-08-31
BRPI0713334A8 (pt) 2018-01-02
KR20090023703A (ko) 2009-03-05
PT3366278T (pt) 2024-10-21
RS57111B1 (sr) 2018-06-29
EA200970047A1 (ru) 2009-04-28
US20220273653A1 (en) 2022-09-01
TW200817008A (en) 2008-04-16
NZ573291A (en) 2011-11-25
MX2009000158A (es) 2009-01-23
CY1120564T1 (el) 2019-07-10
CN101478950B (zh) 2013-02-06
RS65990B1 (sr) 2024-10-31
EP2040671B1 (en) 2018-01-24
US20090176813A1 (en) 2009-07-09
JOP20200160A1 (ar) 2022-10-30
HUE068406T2 (hu) 2024-12-28
LT3366278T (lt) 2024-11-11
KR101406879B1 (ko) 2014-06-13
SI3366278T1 (sl) 2024-12-31
IL195491A0 (en) 2009-09-01
LT2040671T (lt) 2018-05-10
US20150010637A1 (en) 2015-01-08
UY30431A1 (es) 2008-01-31

Similar Documents

Publication Publication Date Title
BRPI0713334A2 (pt) suspensÕes aquaosas de tmc278
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
BR112013025987A2 (pt) derivados de pirimidina para o tratamento de infecções virais
BR112015011036A2 (pt) derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais
BR112015020118A2 (pt) derivados de 2-aminopirimidina para o tratamento de infecções virais
JO2755B1 (en) (Use 2-6- (3-amino-piperidine-1-yl) -3-methyl-2, 4-dioxo-3,4-dihydro-2H-pyrimidine-1-y-methyl-4-fluoro-benzonitrile for the treatment of diabetes, cancer , Autoimmune disorders and HIV infection)
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
BRPI0715893A2 (pt) composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
BR112015007586A2 (pt) derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças
BRPI0712819B8 (pt) composto para liberação controlada de opióides fenólicos, processo para a preparação do referido composto e composição farmacêutica
BRPI0807487A8 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
CL2011000838A1 (es) Compuestos heterociclicos derivados de tetraciclos ortocondensados con un grupo pirimidina 2,4,6-triona espirocondensado, inhibidores de la adn girasa bacteriana; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una infeccion bacteriana.
BR112015003592A2 (pt) derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
PH12020500076A1 (en) Long-acting formulations
TW200806295A (en) Long term treatment of HIV infection
WO2012168885A3 (en) Bisacodyl and its analogues as drugs for use in the treatment of cancer
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
BR112023000220A2 (pt) Formulações de longa ação
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
WO2009006141A3 (en) Authority to read as follows: compositions and methods for treating or controlling infections of the eye a sequelae thereof
TW200709818A (en) Prevention of HIV-infection
CR9108A (es) Prevencion de infecciones endoparasitas verticales

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/06/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.